NT-I7 for Esophageal Cancer

"As suggested by the data found on clinicaltrials.gov, this trial is actively recruiting participants. The listing was first published on January 21st 2021 and has since been revised once more as of September 27th 2022."

"Currently, this medical trial is operating at 4 sites located in Louisville, Fort Worth and Houston as well as other cities. To reduce the need for travel during participation, it is recommended to choose a location closest to your residence."

"Currently, there are 728 clinical studies underway that examine the effectiveness of NT-I7. 82 trials have been deemed Phase 3 and are being conducted at 40292 locations across the world with a concentration in Basel, BE."

"Affirmative. Clinicaltrials.gov documents corroborate that this trial, which was originally announced on January 21st 2021, is actively enrolling patients. Approximately 68 individuals must be recruited from four different medical institutions."

"NT-I7 is conventionally used to treat cancerous tumors. It has shown promise in the treatment of difficult cancers such as melanoma, squamous cell carcinoma and metastatic esophageal adenocarcinoma."

"Due to the lack of efficacy data, NT-I7 was assigned a score of 2 on our safety scale. However, there is clinical evidence that it maintains a certain level of safety when used in Phase 2 trials."

"Since 2012, NT-I7 has been the subject of numerous studies. The inaugural trial was sponsored by Ono Pharmaceutical Co. Ltd and incorporated 659 participants. This data set gained phase 1 & 2 drug approval, leading to an additional 728 active trials in 2354 cities across 49 nations presently."